Zusduri Approved for Recurrent Low-Grade Intermediate-Risk Non–Muscle-Invasive Bladder Cancer

The FDA has approved Zusduri for adult patients with recurrent low-grade intermediate-risk ...

JUNE 14, 2025

Early Real-World Data Positive for NMIBC Immunotherapy

The first real-world outcomes data for nadofaragene firadenovec in patients with BCG-unresponsive ...

MAY 24, 2025

Nivolumab Scores in Bladder and Renal Cancer Trials

Providing adjuvant nivolumab after radical resection continues to yield clinically meaningful disease-free survival ...

APRIL 10, 2025

FDA Approves Imfinzi for Muscle-Invasive Bladder Cancer

The FDA has approved Imfinzi with gemcitabine and cisplatin as neoadjuvant treatment for adults with ...

APRIL 1, 2025

Anktiva Approved for BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer

The FDA approved nogapendekin Anktiva with Bacillus Calmette-Guérin for adult patients with BCG-unresponsive ...

APRIL 24, 2024

Ferring Announces Full Availability of Adstiladrin in the U.S.

Ferring Pharmaceuticals announced that Adstiladrin is now fully available across the U.S. for adult patients with ...

JANUARY 18, 2024

Improving Outcomes in Patients With Bladder Cancer

The immunotherapy Opdivo given after surgery increased bladder cancer patients’ chance of staying cancer-free ...

APRIL 13, 2023

FDA Approves Adstiladrin, First Gene Therapy for Bladder Cancer

Adstiladrin is the first gene therapy for adults with high-risk bacillus Calmette-Guérin (BCG)-unresponsive ...

DECEMBER 21, 2022

Padcev Granted Regular Approval for Locally Advanced or Metastatic UC

The FDA approved enfortumab vedotin-ejfv (Padcev, Astellas Pharma) to treat some adults with locally advanced or ...

JULY 19, 2021

FDA Approves Imfinzi for Advanced Bladder Cancer

Durvalumab is a human monoclonal antibody directed against programmed death ligand-1 (PD-L1), which blocks the ...

MAY 3, 2017